Bioasis is dedicated to delivering hope to patients suffering with neurological diseases and disorders. Our breakthrough science focuses on transporting medicines across the blood-brain barrier, providing a path to hundreds of previously untreatable diseases of the central nervous system.
1 in 6 People Worldwide
Neurological disease affects 1.25 billion people worldwide, and the incidence of these disorders is only increasing. Bioasis is determined to deliver effective treatments to patients suffering with these diseases.
Our Science
A Barrier to Better Health
The blood-brain barrier plays an essential role in protecting the brain from blood-borne disease. However, it also blocks otherwise effective medicine from reaching the brain. Most drugs created to treat central nervous system diseases and disorders fail because they aren't optimally designed to be delivered in sufficient quantities to the brain.
Blood-Brain Barrier
Transporting Treatment
The Bioasis xB3 platform provides researchers with a path for the delivery of treatments across the blood-brain barrier and into the brain. Our technology offers a solution to a problem that for decades has blocked development of effective treatment of neurological disorders.
Our Platform
Latest News
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2018Oct. 30, 2018
Bioasis Announces xB3 ™ Platform Technology Licensing Agreement with ProthenaOct. 29, 2018
Under the terms of the agreement, Bioasis to receive a US$1 million upfront payment from Prothena, plus additional potential option exercise, regulatory and commercial milestone payments, plus additional royalties on net sales from licensed products Prothena will receive a worldwide, exclusive license to use the xB 3 platform with an undisclosed neurodegenerative disease target as well as the option for three additional neuroscience targets
Bioasis Announces Investor Relations Service Agreement with Stern IROct. 4, 2018